Shares of EntreMed ($ENMD) shot up 18% this morning after the developer posted final data on its primary endpoint for the ovarian cancer drug ENMD-2076. Investigators reported that 22% of the 64 patients in the open label, single arm study demonstrated six-month progression-free survival. Four of the patients experienced a partial response and no median survival rate has been established yet. "These results show an increase in the reported progression free survival rate over the presentation of interim data at ASCO and are very encouraging," said EntreMed's chief medical officer, Carolyn F. Sidor. Rockville, MD-based EntreMed ended the second quarter with a $1.7 million loss and $3.8 million in the bank. Release